Ibrutinib, idelalisib, venetoclax provide ‘very exciting developments’ in CLL - Dr Kanti Rai

Ibrutinib, idelalisib, venetoclax provide ‘very exciting developments’ in CLL - Dr Kanti Rai

Just in case you haven't heard the news, 'There have been “very exciting” developments over the last decade in the treatment of CLL, Dr Kanti Rai (of CLL Rai staging fame) told HemOnc Today': healio.com/hematology-oncol...

Neil

1 Reply

oldestnewest
  • Very encouraging to hear from such an expert. 🍻

    Jeff

You may also like...